Patients with refractory angina pectoris have low quality of life and reduced exertional capacity. Studies have shown that the coronary sinus reducer (CSR) implantation improves the quality of life. However, to date there are no firm objective data on improvement of exertional capacity. Studies have shown a large influence of placebo effect after interventional procedures, which is even more pronounced than in medically treated patients. As angina pectoris presents entirely subjective perception of chest discomfort, its improvement may be influenced by this effect in up to 30 %. The investigators will study weather the CSR implantation improves aerobic exertional capacity in comparison to optimal medical therapy alone. Further, the investigators will explore the extent of myocardial reversible ischemia reduction and possible influence on hrECG markers of left ventricular arrhythmogenicity. 40 patients with refractory angina CCS class (Canadian cardiovascular society) II-IV and confirmed reversible ischemia will be included. Patients will be randomized into two groups. The first group will undergo CSR implantation procedure. The second group will present a sham control group with placebo procedure. At inclusion and after 6 months the investigators will perform cardiopulmonary exercise test (CPET), single photon emission tomography for detection of reversible ischemia (SPECT), high resolution ECG (hrECG), echocardiography and asses the subjective burden of angina according to CCS score and the quality of life according to the Seattle angina Questionnaire (SAQ).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
25
Coronary sinus reducer device (Neovasc, Richomnd, Canada) implantation in the coronary sinus. The procedure is performed in the cardiac catheterization laboratory through right internal jugular vein.
Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
University Medical Centre Ljubljana
Ljubljana, Slovenia
Impact of CSR versus placebo procedure on exertional capacity measured by maximal oxygen consumption (VO2) during cardio-pulmonary exercise testing.
Maximal oxygen consumption on cycle spiroergometry using the same ramp exercise protocol during the same part of the day.
Time frame: 6 months
Impact of CSR versus placebo procedure on exercise duration time during cardio-pulmonary exercise testing.
Exercise duration time on cycle spiroergometry using the same continuous exercise protocol during the same part of the day.
Time frame: 6 months
Change in the extent of myocardial reversible ischemia calculated by single-photon emission computed tomography (dynamic scintigraphy).
Dynamic myocardial scintigraphy with the use of a 4 segment model of the left ventricle for calculation of absolute regional perfusion (ml/g/min) during rest and during pharmacologic stress. Change in the extent of myocardial reversible ischemia calculated by single-photon emission computed tomography.
Time frame: 6 months
Change in the extent of myocardial reversible ischemia calculated by single-photon emission computed tomography (static scintigraphy).
Static myocardial scintigraphy with the use of a 17 segment model for the relative calculation of regional perfusion during rest and pharmacologic stress.
Time frame: 6 months
Change in RR interval variability as assessed by hrECG.
5 min recording of hrECG (1000 Hz) for the calculation of RR interval variability.
Time frame: 6 months
Change in late potentials as assessed by hrECG.
5 min recording of hrECG (1000 Hz) for the calculation of late potentials.
Time frame: 6 months
Change in QT variability as assessed by hrECG.
5 min recording of hrECG (1000 Hz) for determination of QT variability.
Time frame: 6 months
Change in Canadian Cardiovascular Society angina pectoris class (CCS).
Change in CCS class I-IV. Acco
Time frame: 3 months, 6 months
Impact of CSR versus placebo procedure on quality of life according to Seattle angina questionnaire (SAQ).
Change in each of the five categories: Physical Limitation Scale (range 1-100), Anginal Stability Scale (range 1-100), Anginal Frequency Scale (range 1-100), Treatment Satisfaction Scale (range 1-100), Disease Perception Scale (range 1-100). Higher values in scale represent better outcome. Subscales are not combined.
Time frame: 3 months, 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.